Trials / Completed
CompletedNCT03470532
Comparing Articaine and Mepivacaine Without Palatal Injection in Pain Assessment During Maxillary Teeth Extraction
Comparing the Effect of 4% Articaine and 2% Mepivacaine Without Palatal Injection in Pain Assessment During Maxillary Teeth Extraction- A Randomized Clinical Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Melaka Manipal Medical College · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study compares the the efficacy of buccal infiltration of 4% Articaine and 2% Mepivacaine without any palatal injection during extraction of maxillary teeth. One group of patient receives buccal infiltration of Articaine and another group receives buccal infiltration of Mepivacaine.
Detailed description
Dense local anesthesia is required to reduce pain during extraction of tooth. Administration of local anesthesia to the palatal mucosa is proved to be the most painful due to its firm adherence to the underlying periosteum and also it's abundant nerve supply. Articaine has greater lipid solubility and high bone penetration property. Mepivacaine is proven to be the safest local anaesthetic agent. Avoidance of a palatal injection during extraction will benefit the patient by reducing pain and anxiety to a greater extent. So this study compares the bone penetration property between Articaine and Mepivacaine by assessing the pain in the palatal mucosa while extracting the tooth using only buccal infiltration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | buccal infiltration of 4% Articaine with Epinephrine | Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge |
| DRUG | buccal infiltration of 2% Mepivacaine with Epinephrine | Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge |
Timeline
- Start date
- 2017-02-25
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2018-03-20
- Last updated
- 2018-03-21
Locations
1 site across 1 country: Malaysia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03470532. Inclusion in this directory is not an endorsement.